Soon P S H, Yeh M W, Delbridge L W, Bambach C P, Sywak M S, Robinson B G, Sidhu S B
University of Sydney Endocrine Surgical Unit, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Eur J Surg Oncol. 2008 Jan;34(1):67-70. doi: 10.1016/j.ejso.2007.03.007. Epub 2007 May 29.
Laparoscopic adrenalectomy has surpassed open adrenalectomy as the gold standard for excision of benign adrenal lesions. The size threshold for offering laparoscopic adrenalectomy is controversial as the prevalence of adrenocortical carcinoma increases with increasing tumour size. The aim of this paper was to assess the safety of laparoscopic adrenalectomy for large adrenal tumours (tumours > or = 60 mm).
A retrospective cohort study of patients who underwent adrenalectomy in a single unit during the period 1995-2005 was undertaken.
One hundred and seventy patients with 173 tumours were included in this study. Of these, 29 were > or = 60 mm in size, and 16 of these patients underwent laparoscopic adrenalectomy. There were 8 adrenocortical carcinomas in the group with tumours > or = 60 mm in size. Five of these patients underwent an open adrenalectomy, while 2 and 1 patients had laparoscopic and laparoscopic converted to open adrenalectomy respectively. Four of the patients undergoing open adrenalectomy died of their disease while 1 is alive with recurrence 3 years later. The 3 patients who underwent either laparoscopic or laparoscopic converted to open adrenalectomy are alive without evidence of disease after 18 months follow up.
Our data show that patients with tumours > or = 60 mm with no preoperative or intraoperative evidence of malignancy can undergo laparoscopic adrenalectomy without evidence of recurrence on short term follow up. These findings are concordant with the growing body of literature supporting laparoscopic adrenalectomy for potentially malignant tumours > or = 60 mm in size without preoperative or intraoperative features of malignancy.
腹腔镜肾上腺切除术已超越开放性肾上腺切除术,成为切除良性肾上腺病变的金标准。随着肾上腺皮质癌的患病率随肿瘤大小增加而上升,进行腹腔镜肾上腺切除术的大小阈值存在争议。本文旨在评估腹腔镜肾上腺切除术治疗大型肾上腺肿瘤(肿瘤直径≥60mm)的安全性。
对1995年至2005年期间在单一科室接受肾上腺切除术的患者进行回顾性队列研究。
本研究纳入了170例患者的173个肿瘤。其中,29个肿瘤直径≥60mm,这些患者中有16例接受了腹腔镜肾上腺切除术。肿瘤直径≥60mm的组中有8例肾上腺皮质癌。其中5例患者接受了开放性肾上腺切除术,2例和1例患者分别接受了腹腔镜肾上腺切除术和腹腔镜转为开放性肾上腺切除术。4例接受开放性肾上腺切除术的患者死于疾病,1例患者在3年后复发存活。3例接受腹腔镜或腹腔镜转为开放性肾上腺切除术的患者在随访18个月后存活且无疾病证据。
我们的数据表明,肿瘤直径≥60mm且术前或术中无恶性证据的患者可接受腹腔镜肾上腺切除术,短期随访无复发证据。这些发现与越来越多的文献一致,这些文献支持对直径≥60mm且无术前或术中恶性特征的潜在恶性肿瘤进行腹腔镜肾上腺切除术。